Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
This study is for people admitted to hospital with severe breathing difficulties, where the lungs can't get enough oxygen. This can sadly lead to more serious conditions. We know a blood marker called IL-6 often goes up before someone gets much sicker. This research wants to see if measuring IL-6 early can help doctors decide when to give treatments like Dexamethasone (a steroid) or Tocilizumab (a medicine that calms down the immune system). The idea is that by giving these treatments sooner, we might be able to prevent patients from needing intensive care or developing other severe issues. We're testing if this approach is practical and helpful for patients.
At a glance
What is this study about?
When your lungs struggle to get enough oxygen into your blood, it's called acute hypoxemic respiratory failure. This can be very serious and sometimes leads to other organs failing or even death. Currently, around 30% of people who need critical care have this condition, so finding better ways to treat it is really important.
Researchers have noticed that a specific marker in the blood called Interleukin-6 (IL-6) often rises several days before a patient with these breathing problems gets much worse – for example, before they need intensive care. The idea behind this study is to see if we can use these IL-6 levels to predict who might get sicker and then give them treatment sooner. By stepping in early, we hope to prevent their condition from becoming more severe.
The study aims to find out if using IL-6 levels to guide treatment is possible and effective. We will be looking at whether giving medicines like Dexamethasone or Tocilizumab based on these blood test results can help people recover better and avoid the most serious outcomes.
Key takeaways
- New study focusing on severe breathing problems in hospital.
- Using a blood marker (IL-6) to guide early treatment.
- Treatments being tested are Dexamethasone and Tocilizumab.
- Aims to prevent patients from getting sicker and needing intensive care.
- Participation involves monitoring and a follow-up six months later.
Who may be eligible?
To be part of this study, you would need to be at least 18 years old and have recently developed new breathing problems, such as a cough, shortness of breath, or needing oxygen, within the last two weeks. You would also need to be admitted to the hospital for treatment.
However, there are some reasons why you might not be able to join. For example, if you can't give your informed consent, or if you've had an allergic reaction to similar medicines in the past. Also, if you already have certain other health conditions like an active tuberculosis infection, severe liver problems, or very low blood counts, you wouldn't be able to participate. We also can't include pregnant or breastfeeding individuals, or those already in intensive care or needing immediate breathing support.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you recently developed new breathing problems and been admitted to hospital?
- Are you able to provide consent for yourself?
- Do you have any severe liver problems or very low blood counts?
- Are you pregnant or breastfeeding?
What does participation involve?
If you are eligible and agree to take part, your IL-6 blood levels will be checked over two days. If your IL-6 levels are high, you will then be randomly assigned to one of three groups: you might receive the standard hospital care, or standard care plus a single drip (intravenous infusion) of Tocilizumab, or standard care plus Dexamethasone tablets for 10 days. You will be monitored in the hospital until you are discharged, or for up to 28 days. Around six months after you leave the hospital, there will be a follow-up phone call to see how you are doing. The total duration of your active participation, including follow-up, will be around 6 months.
Potential risks and benefits
Locations (1)
- Toronto General HospitalVerified postcodeToronto, Canada· Recruiting
Common questions
What is IL-6?
IL-6 is a small protein in your blood that increases when your body has inflammation or an infection. In this study, we're looking at its levels to help guide treatment.
What are Dexamethasone and Tocilizumab?
Dexamethasone is a type of steroid that helps reduce inflammation. Tocilizumab is a medicine that helps calm down an overactive immune response.
Will I definitely receive one of these new treatments?
No, if your IL-6 levels are not high, you won't. If they are high, you will be randomly put into one of three groups: standard care only, standard care plus Tocilizumab, or standard care plus Dexamethasone.
What does 'randomly assigned' mean?
It means like flipping a coin. You or your doctor won't choose which group you are in; it will be decided by chance to make the study fair.
How long will the study follow me?
You'll be observed while in hospital or for up to 28 days, and then there will be a follow-up phone call about six months after that.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.